The Impact of Newer Biological Disease Modifying Anti-Rheumatic Drugs on Cardiovascular Risk Factors: A 12-Month Longitudinal Study in Rheumatoid Arthritis Patients Treated with Rituximab, Abatacept and Tociliziumab

Open Access

Peer-reviewed

Research Article

Sella Aarrestad Provan ,

* E-mail: sellaprovan@gmail.com

Affiliation Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway
⨯
Inger Jorid Berg,

Affiliation Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway
⨯
Hilde Berner Hammer,

Affiliation Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway
⨯
Alexander Mathiessen,

Affiliation Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway
⨯
Tore Kristian Kvien,

Affiliation Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway
⨯
Anne Grete Semb

Affiliation Preventive Cardio-Rheuma clinic, Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway
⨯

Reader Comments (0)

Cardiovascular diseases
Is the Subject Area "Cardiovascular diseases" applicable to this article?

Thanks for your feedback.
Cholesterol
Is the Subject Area "Cholesterol" applicable to this article?

Thanks for your feedback.
C-reactive proteins
Is the Subject Area "C-reactive proteins" applicable to this article?

Thanks for your feedback.
Medical risk factors
Is the Subject Area "Medical risk factors" applicable to this article?

Thanks for your feedback.
Lipoproteins
Is the Subject Area "Lipoproteins" applicable to this article?

Thanks for your feedback.
Blood pressure
Is the Subject Area "Blood pressure" applicable to this article?

Thanks for your feedback.
Rheumatoid arthritis
Is the Subject Area "Rheumatoid arthritis" applicable to this article?

Thanks for your feedback.
Cancer risk factors
Is the Subject Area "Cancer risk factors" applicable to this article?

Thanks for your feedback.